Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.

Critical reviews in oncology/hematology - 1 Jan 2021

Imyanitov Evgeny N, Iyevleva Aglaya G, Levchenko Evgeny V

Abstract excerpt

Molecular testing has become a mandatory component of the non-small cell lung cancer (NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the analysis of ALK, ROS1, RET and NTRK translocations have already been incorporated in the NSCLC diagnostic standards, and the inhibitors of these kinases are in routine clinical use. There are emerging biomarkers, e.g., KRAS G12C substitutions and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 33316418
DOI: 10.1016/j.critrevonc.2020.103194

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.PMID 33316418Read ↗

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Semantic proximity Read ↗

Current status of molecular diagnostics for lung cancerSemantic proximity Read ↗

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].Semantic proximity Read ↗

Precision medicine in non-small cell lung cancer: Current applications and future directions.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Prognostic and predictive biomarkers in non-small cell lung carcinoma.Semantic proximity Read ↗

Molecular Testing of Lung CancersSemantic proximity Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

Molecular Diagnostics in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.